Amplifying Antitumor Immunity with IPSC-derived Exosomes
Overview
Overview
Journal
Mol Ther
Publisher
Cell Press
Specialties
Molecular Biology
Pharmacology
Pharmacology
Date
2023 Jul 19
PMID
37467746
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Koerner J, Horvath D, Herrmann V, MacKerracher A, Gander B, Yagita H
. PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nat Commun. 2021; 12(1):2935.
PMC: 8131648.
DOI: 10.1038/s41467-021-23244-3.
View
2.
Shubhra Q, Alam A
. Harnessing the potential of lipid nanoparticles for the delivery of chemically modified siRNA to combat hepatic adenovirus infection. Mol Ther Nucleic Acids. 2023; 33:44-46.
PMC: 10336070.
DOI: 10.1016/j.omtn.2023.06.005.
View
3.
Ke W, Afonin K
. Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs). Adv Drug Deliv Rev. 2021; 176:113835.
PMC: 8440450.
DOI: 10.1016/j.addr.2021.113835.
View
4.
Saxena M, Bhardwaj N
. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. Trends Cancer. 2018; 4(2):119-137.
PMC: 5823288.
DOI: 10.1016/j.trecan.2017.12.007.
View
5.
Huda M, Nurunnabi M
. Potential Application of Exosomes in Vaccine Development and Delivery. Pharm Res. 2022; 39(11):2635-2671.
PMC: 8757927.
DOI: 10.1007/s11095-021-03143-4.
View